2015
Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLOS ONE 2015, 10: e0116694. PMID: 25658949, PMCID: PMC4320073, DOI: 10.1371/journal.pone.0116694.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCosts and Cost AnalysisFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPrevalenceRetrospective StudiesSubstance-Related DisordersUnited StatesConceptsQuality-adjusted life yearsOpioid substitution therapyHIV infectionHIV incidenceHIV prevalenceEvidence-based risk reduction interventionDynamic HIV transmission modelHolistic Health Recovery ProgramBehavioral HIV prevention interventionsFuture HIV incidenceTotal medical costsHIV transmission modelHIV prevention interventionsGeneral adult populationRisk reduction interventionsCost-effectiveness analysisSubstitution therapySexual transmissionHIV programsPrevention interventionsMedical costsTreatment settingsLife yearsReduction interventionsUS population
1999
Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy
Engles‐Horton L, Skowronski C, Mostashari F, Altice F. Clinical Guidelines and Pharmacist Intervention Program for HIV‐Infected Patients Requiring Granulocyte Colony‐Stimulating Factor Therapy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 1999, 19: 356-362. PMID: 10221375, DOI: 10.1592/phco.19.4.356.30938.Peer-Reviewed Original ResearchConceptsIntervention periodPreintervention periodFactor therapyG-CSFGranulocyte colony-stimulating factor therapyHuman immunodeficiency virus (HIV) infectionColony-stimulating factor therapyPharmacist intervention programPharmacist-based interventionMean hospital stayImmunodeficiency virus infectionHospital medical information systemG-CSF dosesNumber of patientsMedical house staffTherapeutics subcommitteeHospital stayPharmacist interventionsChart reviewHospitalized patientsClinical pharmacistsImmunodeficiency syndromePatient morbidityPharmacy costsClinical guidelines